SUSTAIN trial programme (revision 2)
Old revision·03:53, 18 Jul 2024·NNT_Nerys
This is an old revision of this page, as it stood at 03:53, 18 Jul 2024, saved by NNT_Nerys with the summary add the number randomised and the number completing. It may differ substantially from the current revision, and any error it contains may since have been corrected.
| SUSTAIN trial programme | |
|---|---|
| Drug | Semaglutide 0.5 and 1.0 mg weekly |
| Indication | Type 2 diabetes |
| Notable member | SUSTAIN 6, cardiovascular outcomes |
| Topic infobox · conventions | |
The SUSTAIN trial programme is the phase 3 series that established weekly semaglutide for type 2 diabetes. Its trials compared semaglutide against placebo and against active comparators including sitagliptin, exenatide extended-release, insulin glargine and dulaglutide.[1]
Across the programme, semaglutide 1.0 mg reduced glycated haemoglobin by roughly 1.5–1.8 percentage points from baseline, with weight reduction of about 4–6 kg — substantially less than the 2.4 mg obesity dose studied in STEP.[1]